GLI2 but Not GLI1/GLI3 Plays a Central Role in the Induction of Malignant Phenotype of Gallbladder Cancer
ONCOLOGY REPORTS 45: 997-1010, 2021 GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer SHU ICHIMIYA1, HIDEYA ONISHI1, SHINJIRO NAGAO1, SATOKO KOGA1, KUKIKO SAKIHAMA2, KAZUNORI NAKAYAMA1, AKIKO FUJIMURA3, YASUHIRO OYAMA4, AKIRA IMAIZUMI1, YOSHINAO ODA2 and MASAFUMI NAKAMURA4 Departments of 1Cancer Therapy and Research, 2Anatomical Pathology, 3Otorhinolaryngology and 4Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan Received August 10, 2020; Accepted December 7, 2020 DOI: 10.3892/or.2021.7947 Abstract. We previously reported that Hedgehog (Hh) signal Introduction was enhanced in gallbladder cancer (GBC) and was involved in the induction of malignant phenotype of GBC. In recent Gallbladder cancer (GBC) is the seventh most common gastro- years, therapeutics that target Hh signaling have focused on intestinal carcinoma and accounts for 1.2% of all cancer cases molecules downstream of smoothened (SMO). The three tran- and 1.7% of all cancer-related deaths (1). GBC develops from scription factors in the Hh signal pathway, glioma-associated metaplasia to dysplasia to carcinoma in situ and then to invasive oncogene homolog 1 (GLI1), GLI2, and GLI3, function down- carcinoma over 5‑15 years (2). During this time, GBC exhibits stream of SMO, but their biological role in GBC remains few characteristic symptoms, and numerous cases have already unclear. In the present study, the biological significance of developed into locally advanced or metastasized cancer by the GLI1, GLI2, and GLI3 were analyzed with the aim of devel- time of diagnosis. Gemcitabine (GEM), cisplatin (CDDP), and oping novel treatments for GBC.
[Show full text]